Many low-income and moderate-income U.S. adults say they would be willing to pay about $18 extra per month for generous coverage for specialty drugs.
A team of researchers backed by Bristol-Myers Squibb Company, New York (NYSE:BMY) — a pharmaceutical company — has presented that finding in a survey report published in the latest issue of Health Affairs, a peer-reviewed academic journal that focuses on health care finance and health care organization.
The team included John Romley, a professor at the University of Southern California (USC); Yuri Sanchez, an economist at Precision Health Economics L.L.C., Los Angeles; Dana Goldman, a professor at USC; and John Penrod, an economist at Bristol-Myers.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
